A review on schizophrenia and relapse—a quest for user‐friendly psychopharmacotherapy

Suzuki, Takefumi; Uchida, Hiroyuki; Takeuchi, Hiroyoshi; Tsuboi, Takashi; Hirano, Jinichi; Mimura, Masaru

doi:10.1002/hup.2421

Cited by 29 publications

(24 citation statements)

References 178 publications

(174 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of the caregivers experienced significant stress caused by their ill relatives’ refusal to take medications or to attend follow‐up consultations. Among people with schizophrenia, poor medication adherence is a major issue that brings about negative clinical impacts and relapses , which subsequently intensify caregiver burden . Current evidence has indicated that the use of long‐acting injectable antipsychotics (LAIs) can enhance treatment adherence, reduce relapse rates and improve prognosis in people with schizophrenia .…”

Section: Discussionmentioning

confidence: 99%

“…Among people with schizophrenia, poor medication adherence is a major issue that brings about negative clinical impacts and relapses, 18 which subsequently intensify caregiver burden. 19 Current evidence has indicated that the use of long-acting injectable antipsychotics (LAIs) can enhance treatment adherence, reduce relapse rates and improve prognosis in people with schizophrenia. 20,21 Moreover, a recent post hoc analysis revealed that, for people on prior oral antipsychotics after switching to LAIs, caregiver burden was significantly alleviated, with reductions in workdays missed, leisure time affected and time spent in caregiving.…”

Section: Stress and Burden Faced By Family Caregiversmentioning

confidence: 99%

See 1 more Smart Citation

Stress and burden faced by family caregivers of people with schizophrenia and early psychosis in Hong Kong

Wan

Wong

2019

Internal Medicine Journal

View full text Add to dashboard Cite

Background/Aim Families, especially in Chinese society, play a crucial role in care provision for relatives with schizophrenia, but the burden of caregiving has shown to cause significant distress among caregivers. The aim of the study is to assess the degree of stress and burden among caregivers of relatives with schizophrenia and early psychosis in Hong Kong. Methods A cross‐sectional survey was conducted in 454 caregivers recruited from two mental health non‐governmental organisations and the outpatient clinic of a psychiatric hospital. Data were collected through a questionnaire administered via face‐to‐face or telephone interview. Results Caregivers attributed most of their conflicts with the ill relative or other family members to their own lack of knowledge of patient symptoms (56.4%), other family members’ lack of knowledge of patient symptoms (46.9%) or the ill relative's refusal to take medications (43.0%). Most of the caregivers had corresponding stress scores of 5 (scale: 1–5; mean = 3.88, 3.85 and 4.19, respectively). Nearly, a third (30.2%) of the caregivers surveyed reported an overall stress score of 5 (mean = 3.56). Regarding psychosocial problems, 78.0%, 49.8% and 45.8% of caregivers experienced anxiety, reduced socialising and insomnia, respectively. Conclusions Caregivers of relatives with schizophrenia and early psychosis experience significant stress and psychosocial burden. To help them cope with distress, community support services should be strengthened. Moreover, long‐acting injectable antipsychotics are worth considering to alleviate caregiver burden due to ill relatives’ medication compliance issues.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Stress and Burden Faced By Family Caregiversmentioning

confidence: 99%

Stress and burden faced by family caregivers of people with schizophrenia and early psychosis in Hong Kong

Wan

Wong

2019

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…There were four patients who were successfully withdrawn from antipsychotic treatment. Compared with those who needed continuous antipsychotic treatment in the same unit (n¼ 51), they were significantly older (77.078.6 versus 56.0 712.1 y.o., p o0.01) and had been treated with a fewer number of total psychotropics at baseline (1.50 71.00 versus 4.947 1.93 agents, p o0.001) by Mann-Whitney U-Test; details were summarized elsewhere (Suzuki, et al, 2014).…”

Section: Resultsmentioning

confidence: 99%

“…Many difficult patients were successful to be treated with a twice-daily or even single-night dosing (Suzuki et al, 2005); which would be important in the interest of consumers for convenience as poor adherence is a well-established factor for relapse in schizophrenia (Suzuki et al, 2014) and plausibly, patients generally prefer once daily dosing to more complex schedules (Witticke et al, 2012). This may be also positive for caregivers and nursing staff by reducing the burden of giving the medicines frequently on a regular basis.…”

Section: Discussionmentioning

confidence: 97%

Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year

Suzuki

Uchida

Takeuchi

et al. 2015

Psychiatry Research

Self Cite

View full text Add to dashboard Cite

“…Non-adherence to antipsychotic treatment has been associated with relapses, poorer life satisfaction, substance-and alcohol abuse and even suicides 18,19 . Besides inducing hazards for the patient, these outcomes may www.nature.com/scientificreports www.nature.com/scientificreports/ also stress parents or other caregivers significantly 20 . The burden on parents of the patient with the disorder is often presented as informal caregiving, i.e.…”

mentioning

confidence: 99%

Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring

Taipale

Rahman

Tanskanen

et al. 2020

Sci Rep

View full text Add to dashboard Cite

This study aimed to identify if antipsychotic exposure in offspring is associated with psychiatric and non-psychiatric healthcare service use and work disability of their parents. this Swedish populationbased cohort study was based on data comprising 10,883 individuals with schizophrenia, who had at least one identifiable parent in the nationwide registers, and their parents (N = 18,215). The registerbased follow-up during 2006-2013 considered the level of antipsychotic exposure and persistence of use of the offspring, further categorized into first (FG) and second generation (SG) antipsychotics, and orals versus long-acting injections (LAIs). The main outcome measure was parental psychiatric healthcare service use, secondary outcomes were non-psychiatric healthcare use and long-term sickness absence. SG-LAI use was associated with a decreased risk (relative risks [RR] 0.81-0.85) of parental psychiatric healthcare use compared with not using SG-LAI, whereas oral antipsychotics were associated with an increased risk (RRs 1.10-1.29). Both FG-and SG-LAI use by the offspring were associated with a lower risk of long-term sickness absence (range of odds ratios 0.34-0.47) for the parents, compared with nonuse of these drugs. The choice of antipsychotic treatment for the offspring may have an impact on work disability and healthcare service use of their parents.

show abstract

A review on schizophrenia and relapse—a quest for user‐friendly psychopharmacotherapy

Abstract: Bearing in mind that suboptimal adherence and withdrawal from antipsychotics are an established and unequivocal risk factor for relapse, further investigations are certainly needed to explore user-friendly manner of psychopharmacotherapy to prevent relapse in schizophrenia.

Cited by 29 publications

References 178 publications

Stress and burden faced by family caregivers of people with schizophrenia and early psychosis in Hong Kong

Stress and burden faced by family caregivers of people with schizophrenia and early psychosis in Hong Kong

Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year

Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring

Contact Info

Product

Resources

About